Newsroom

News

The latest updates from Kangrong Pharmaceuticals.

Team Photo

5 Aug 2026

Strengthening University–Industry Collaboration: Bozhou University Pharmacy Faculty and Students Visit Our Company

To further strengthen university–industry collaboration, promote the integration of education and industry, support the development of pharmaceutical professionals, and provide a platform connecting academic learning with industry practice, approximately 160 faculty members and students from the Pharmacy Program of Bozhou University visited our company in two groups on May 28 and June 23, 2026. To ensure that the visits were conducted safely, efficiently, and in an orderly manner, our Human Resources & Administration Department, Production Department, Quality Department, and other relevant teams worked closely together to make comprehensive preparations in advance. These included safety inspections of the facility, planning of visitor routes, coordination of guides, and access control for clean production areas. During the visits, department representatives provided detailed introductions to our production safety management systems, modern pharmaceutical manufacturing processes, and Quality Control (QC) procedures. Faculty members and students toured key areas of the company, including the clean production workshops and quality control laboratories, gaining first-hand insight into the standardized, regulated, and highly refined operations of a modern pharmaceutical company. Through this on-site learning experience, the visiting faculty and students gained a more comprehensive understanding of the entire pharmaceutical manufacturing process and the stringent quality and safety requirements of the pharmaceutical industry. The visit also helped reinforce their theoretical knowledge while providing a closer look at our rigorous quality management system and standardized corporate operations. At the same time, this university–industry exchange provided an opportunity to showcase our professional corporate culture, well-managed production environment, and established talent development system. It further strengthened the foundation for cooperation between the university and our company while enhancing our corporate presence and industry engagement. Going forward, Kangrong Pharmaceutical will continue to deepen university–industry collaboration in talent development and regularly carry out cooperative programs such as student visits, industry orientation programs, internships, and employment-related practical training. We remain committed to fulfilling our corporate social responsibility and contributing to the development of highly skilled professionals for the pharmaceutical industry.

Read more
Great News! Kangrong Pharmaceutical’s Tigecycline for Injection Approved

2 Jul 2026

Great News! Kangrong Pharmaceutical’s Tigecycline for Injection Approved

Beijing Rongying Pharmaceutical Technology Co., Ltd. has received the Drug Registration Certificate for Tigecycline for Injection issued by the relevant regulatory authority, with the drug approval number NMPA Approval No. H20265029 . Rongying Pharmaceutical is the R&D subsidiary of Kangrong Pharmaceutical. Tigecycline for Injection , available in a 50 mg strength, is indicated for the treatment of patients aged 18 years and older with complicated intra-abdominal infections caused by susceptible bacteria, including Citrobacter freundii , Escherichia coli , and Bacteroides fragilis ; complicated skin and soft tissue infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA); and community-acquired bacterial pneumonia.

Read more
Great News! Kangrong Pharmaceutical’s Levofloxacin Eye Drops Approved

15 Jun 2026

Great News! Kangrong Pharmaceutical’s Levofloxacin Eye Drops Approved

Kangrong Pharmaceutical has received the Drug Registration Certificate for Levofloxacin Eye Drops issued by the relevant regulatory authority, with the drug approval number NMPA Approval No. H20264702 . Levofloxacin Eye Drops , strength: 0.488% (5 mL: 24.4 mg) (calculated as C₁₈H₂₀FN₃O₄), are primarily indicated for the treatment of blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomianitis, and keratitis, as well as for antimicrobial prophylaxis during the perioperative period in ophthalmic surgery.

Read more
Officials from the Anhui Provincial Medical Products Administration Visit Our Company for an Inspection and Research Tour

8 May 2026

Officials from the Anhui Provincial Medical Products Administration Visit Our Company for an Inspection and Research Tour

On April 22, 2026, Zhang Lei, Member of the Party Leadership Group and Deputy Director of the Anhui Provincial Medical Products Administration, together with Wang Changxiang, Director of the Drug Manufacturing Supervision Division, and other officials, visited Kangrong Pharmaceutical to learn about the company’s development and quality management practices. During the visit, the delegation held an in-depth discussion with company representatives regarding business operations and the company’s practical needs. At the meeting, General Manager Yang Chunjie provided the delegation with a detailed overview of the company’s current development and future plans, production arrangements for existing products, and registration applications for products under development. Particular emphasis was placed on the contract manufacturing and quality assurance of Moxifloxacin Hydrochloride and Sodium Chloride Injection, a product included in China’s centralized procurement program. Deputy Director Zhang recognized the company’s positive development momentum and strong commitment to quality management, encouraging Kangrong Pharmaceutical to continue expanding and strengthening its business. He also provided comprehensive responses to the practical challenges raised by the company and expressed close attention to its development needs. Deputy Director Zhang further emphasized that pharmaceutical safety is directly related to public health and well-being. He urged the company to maintain its current positive momentum, strictly comply with the requirements and guidelines issued by the National Medical Products Administration (NMPA) and the Anhui Provincial Medical Products Administration, and place particular emphasis on post-marketing risk management to ensure the safety and health of patients. On behalf of the company, General Manager Yang Chunjie expressed his appreciation to the Anhui Provincial Medical Products Administration for fostering a supportive business environment and establishing effective communication and service mechanisms. He reaffirmed Kangrong Pharmaceutical’s commitment to continuously strengthening its core competitiveness and contributing to the sustainable development and advancement of the pharmaceutical industry.

Read more
Great News! Kangrong Pharmaceutical’s Lacosamide Oral Solution Approved

6 Jan 2026

Great News! Kangrong Pharmaceutical’s Lacosamide Oral Solution Approved

Kangrong Pharmaceutical’s Lacosamide Oral Solution has recently received regulatory approval, with the drug approval number NMPA Approval No. H20256504 . The product is available in a strength of 200 mL: 2 g . Lacosamide is an analogue of D-serine, an endogenous amino acid that acts as a modulator of NMDA receptors. In vitro electrophysiological studies have shown that lacosamide selectively enhances the slow inactivation of voltage-gated sodium channels (VGSCs), thereby stabilizing hyperexcitable neuronal membranes. Lacosamide Oral Solution is primarily indicated as adjunctive therapy for the treatment of partial-onset seizures in patients with epilepsy aged 4 years and older.

Read more
Kangrong Pharmaceutical’s Memantine Hydrochloride Oral Solution Approved

23 Dec 2025

Kangrong Pharmaceutical’s Memantine Hydrochloride Oral Solution Approved

Anhui Kangrong Pharmaceutical Co., Ltd.’s Memantine Hydrochloride Oral Solution has recently received regulatory approval, with the drug approval number NMPA Approval No. H20256289 . The product is available in a strength of 120 mL: 0.24 g . Memantine Hydrochloride Oral Solution is clinically indicated for the treatment of moderate to severe Alzheimer’s dementia. Its mechanism of action primarily involves antagonism of NMDA receptors, helping to reduce neuronal damage and improve cognitive function.

Read more